Pramodini Medicare (NSE:PRAMODINI) Research & Development: ₹0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:PRAMODINI Pramodini Medicare Ltd NSE:PRAMODINI
19 GF Score
Price ₹114.80
! 1 Warning Sign
View Full Analysis

What is Pramodini Medicare Research & Development?

Pramodini Medicare NSE:PRAMODINI -2.01% 19 Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus rates NSE:PRAMODINI with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Pramodini Medicare's Research & Development for the three months ended in Mar. 2026 was ₹0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil.

Pramodini Medicare  (NSE:PRAMODINI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pramodini Medicare Research & Development Related Terms

Pramodini Medicare Research & Development Historical Data

* Premium members only.

The historical data trend for Pramodini Medicare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pramodini Medicare Research & Development Chart

Pramodini Medicare Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Research & Development
0.00 0.00 0.00 0.00

Pramodini Medicare Quarterly Data
Mar23 Mar24 Mar25 Dec25 Mar26
Research & Development 0.00 0.00 0.00 0.00 0.00
NSE:PRAMODINI
19GF Score
Pramodini Medicare Ltd NSE:PRAMODINI
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pramodini Medicare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.0 Mil mean?
Pramodini Medicare (NSE:PRAMODINI) has a Research & Development of ₹0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Pramodini Medicare and its competitors.
Is Pramodini Medicare's Research & Development too high?
Pramodini Medicare's current Research & Development is ₹0.0 Mil. Overall, Pramodini Medicare has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pramodini Medicare's Research & Development compare to HCA and THC?
Pramodini Medicare's Research & Development of ₹0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Pramodini Medicare and its competitors. Pramodini Medicare's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pramodini Medicare stock overvalued right now?
Pramodini Medicare (NSE:PRAMODINI) has a current Research & Development of ₹0.0 Mil. The current Research & Development is ₹0.0 Mil. Pramodini Medicare's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Pramodini Medicare (NSE:PRAMODINI), the current Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pramodini Medicare Business Description

Address Prakasam Road, D. No: - 29-4-54K, CSI Complex, Suryaraopet, Vijayawada, AP, IND, 520002
Pramodini Medicare Ltd is a diagnostic service provider in India. It provides a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. The company also provide teleradiology services, which functions on a 24*7 basis throughout the year. It provides healthcare services for core testing, patients diagnosis, disease prevention and monitoring of various health conditions. Its services includes both routine and specialized tests, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of diseases.
19GF Score

Get the complete analysis for NSE:PRAMODINI

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹114.80
Price